Business Wire

Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman

21.11.2019 21:02:00 EET | Business Wire | Press release

Share

Carbon (www.carbon3d.com), the world’s leading digital manufacturing platform, announced today that Ellen J. Kullman, former Chairman and CEO of DuPont, has been named President and CEO of the company and Dr. Joseph M. DeSimone has been named Executive Chairman of the Board, effective immediately. Kullman will also remain on Carbon’s board of directors where she has served since 2016. Today’s leadership announcements are the result of a succession plan that DeSimone, Kullman, and members of the board have worked on to prepare the company for its next chapter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005835/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman (Photo: Business Wire)

Carbon has been strengthening its leadership bench over the past several months to support the growth of the business. As President and CEO, Kullman will lead the development and execution of short- and long-term strategies, positioning Carbon to continue delivering value to its employees, customers, partners, and shareholders around the world. DeSimone is transitioning into the role of Executive Chairman to focus on growing mainstream adoption of the Carbon Digital Manufacturing Platform and evangelizing the company’s vision to existing and prospective customers, partners, and the public.

“Today’s announcement is a great honor,” said Kullman. “I am privileged to have spent the last few years on the Carbon board working alongside Joe, one of the greatest entrepreneurs and scientists of our time. Joe has built Carbon into the world’s leading digital manufacturing platform, and as President and CEO of Carbon, I am excited to partner with Joe and build on the solid foundations he’s put into place.”

“For the last six years, I have led Carbon as Chief Executive Officer and am enormously proud of what we’ve accomplished during my tenure,” said DeSimone. “I know what we will accomplish under Ellen will be even more extraordinary. Ellen is the right person to lead Carbon today. She has broad experience across multiple businesses, cycles, and geographies. Her vision, outstanding leadership traits, and distinguished track record will continue to drive Carbon’s growth into the future. In assuming the Executive Chairman role, I will be able to focus on evangelizing the platform and driving adoption more widely.”

Prior to joining DuPont in 1988, Kullman worked for Westinghouse and General Electric. DuPont's board of directors elected Kullman President and a director of the company in October 2008 and Chief Executive Officer in January 2009. She was the nineteenth executive and the first woman to lead the company in its 212-year history. As a business leader, Kullman led double-digit growth of the company’s Safety and Protection business portfolio and started two successful high-growth businesses known today as DuPont Industrial Biosciences and DuPont Sustainable Solutions. During her seven years as CEO, Kullman led the company’s focus on growth in emerging international markets and championed the power of DuPont science and global market knowledge to transform industries. She executed a strong plan and decisively positioned the company for its next generation of growth.

Kullman is co-chair of the Paradigm for Parity coalition and a board director of United Technologies, Dell Technologies, Amgen, and Goldman Sachs. She is a member of the U.S. National Academy of Engineering and past president of the U.S. China Business Council. She serves on the board of trustees of Northwestern University. Kullman has been named one of the “50 Most Powerful Women in Business” by Fortune and one of the “World’s Most Powerful Women” by Forbes. She holds a B.S. in Mechanical Engineering from Tufts University and an MBA from the Kellogg School of Management of Northwestern University.

As co-founder of Carbon, DeSimone took on 3D printing by bringing together insights from diverse fields to co-invent the core technology that now drives the Carbon Platform. Powered by Digital Light Synthesis™ (DLS™) technology, the Carbon Platform is enabling companies to break free of traditional polymer manufacturing methods to advance product innovation. Just this week, he was recognized for his achievements by EY as the U.S. Entrepreneur of the Year.

Before founding Carbon in 2013, DeSimone was a professor at the University of North Carolina for over 20 years. DeSimone has made scientific breakthroughs in areas including green chemistry, medical devices, and nanotechnology, also co-founding several companies based on his research. At UNC, DeSimone built a strong culture in his research group centered on the notion that diversity is a fundamental tenet of innovation.

DeSimone has achieved international recognition as a scientist, inventor, and entrepreneur, earning major accolades including the U.S. Presidential Green Chemistry Challenge Award and the Lemelson-MIT Prize. In 2016, President Obama awarded DeSimone the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. He is also one of only roughly 20 individuals elected to all three U.S. National Academies—the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering.

About Carbon

Carbon’s mission is to reinvent how polymer products are designed, engineered, manufactured, and delivered towards a digital and sustainable future. Based in Silicon Valley, Carbon brings together innovations in software, hardware, and material science to deliver industry-leading digital manufacturing solutions. With Carbon’s ground-breaking Digital Light Synthesis™ technology and broad family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and time to market. To learn more, visit www.Carbon3d.com, like the Carbon Facebook page, or follow Carbon on Instagram and Twitter at @Carbon.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Iska Hain Saric, Head of Strategic Communications, pr@carbon3d.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye